Top 10 Buprenorphine (Subutex) Generic Manufacturers in China
The global demand for opioid addiction treatments, particularly buprenorphine, has surged in recent years due to rising addiction rates and an increased focus on harm reduction strategies. In 2022, the global buprenorphine market was valued at approximately $3.5 billion, with projections suggesting it could reach $5 billion by 2027. China has emerged as a significant player in the production of buprenorphine generics, driven by both domestic needs and export opportunities to various markets, including the United States and Europe.
1. Zhejiang Huahai Pharmaceutical Co., Ltd.
Zhejiang Huahai is one of the leading manufacturers of buprenorphine in China, with a production capacity of over 100 tons annually. The company holds a substantial market share in both domestic and international markets, primarily exporting to Europe and North America, contributing to approximately 20% of China’s buprenorphine exports.
2. Jiangsu Hengrui Medicine Co., Ltd.
Hengrui Medicine is known for its innovative approach to pharmaceutical manufacturing. It has a significant presence in the buprenorphine market, with production volumes exceeding 50 tons per year. The company has been expanding its global footprint, capturing around 15% of the global market share for buprenorphine generics.
3. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
With a robust production capacity and a strong distribution network, Baiyunshan is a key player in the buprenorphine market. The company produces approximately 30 tons of buprenorphine annually, focusing heavily on the domestic market while also exporting to Southeast Asia, holding about 10% of the market share.
4. Tianjin Tasly Pharmaceutical Group Co., Ltd.
Tasly is recognized for its extensive pharmaceutical portfolio, including buprenorphine. The company has a production capacity of around 25 tons per year and has been successful in securing contracts with various international distributors, contributing to roughly 8% of the market share in generics.
5. Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Jianfeng Pharmaceutical specializes in various generics, including buprenorphine. The company produces approximately 20 tons per year and has been increasing its export activities, particularly to Europe and North America, capturing about 5% of the global market share.
6. Anhui BBCA Pharmaceutical Co., Ltd.
BBCA is a notable manufacturer in the pharmaceutical industry, with a focus on producing high-quality generics. They have a capacity to produce 15 tons of buprenorphine annually and are known for their competitive pricing and reliable supply chain, holding around 4% of the market share.
7. Chongqing Yuhua Pharmaceutical Co., Ltd.
Yuhua Pharmaceutical produces around 10 tons of buprenorphine each year and has been expanding its reach in international markets. The company is recognized for its commitment to quality and compliance, securing approximately 3% of the market share globally.
8. Hubei Zhonke Pharmaceutical Co., Ltd.
Zhonke Pharmaceutical has established itself as a reliable producer of buprenorphine, with an annual production volume of 8 tons. The company focuses on maintaining high production standards and has managed to capture about 2% of the global buprenorphine market.
9. Jiangxi Daming Pharmaceutical Co., Ltd.
Daming Pharmaceutical produces around 6 tons of buprenorphine annually, primarily for the domestic market. The company has been making strides in exporting to neighboring countries, holding a market share of roughly 1.5% in the global arena.
10. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Yiling Pharmaceutical is recognized for its commitment to research and development. With an annual production capacity of 5 tons of buprenorphine, the company is actively expanding its international partnerships, controlling about 1% of the global market share.
Insights
The buprenorphine market in China is set to grow significantly, driven by increasing global demand and the country’s robust manufacturing capabilities. As of 2023, China’s share of the global buprenorphine market is approximately 50%, with exports projected to increase by 10% annually over the next five years. The push for generic medications and the rising need for opioid addiction treatments are creating opportunities for manufacturers. Companies are increasingly focusing on compliance and quality standards to meet international regulations, ensuring sustained growth in this competitive landscape.
Related Analysis: View Previous Industry Report
